在服用阿米奥达龙后解决状细胞危机
Paul Silaghi1, Daniel T Eitzman1
1Internal Medicine/Cardiology, University of Michigan, Michigan (USA).
European journal of case reports in internal medicine
|June 12, 2023
概括
阿米奥达龙可以通过影响红细胞脂质来改善状细胞疾病,从而减少状细胞和贫血. 需要进一步的临床试验来确认这种潜在的状细胞危机治疗方法.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 状细胞病 (SCD) 是一种常见的血液疾病,红细胞状机制尚不完全理解.
- 一名患有SCD和心房的患者经历了严重的危机,包括急性胸部综合征,耐受抗生素和红细胞输血等标准治疗.
研究的目的:
- 报告在阿米奥达龙给药后,状细胞危机症状和贫血明显改善的病例.
- 探索阿米奥达龙在改善红细胞形和改善SCD贫血中的潜在作用.
主要方法:
- 一名患有耐火状细胞危机的患者接受了静脉注射阿米奥达龙治疗,用于治疗相关的脑上脉高心率和心房动.
- 在阿米奥达龙治疗期间,监测了临床反应,包括心率控制,血压,血红蛋白水平和症状缓解.
主要成果:
- 阿米奥达龙有效地控制了患者的快速心率,并将心房动转换为鼻节奏.
- 开始服用阿米奥达龙后,患者的症状明显改善,血红蛋白水平显著上升,持续到出院.
- 患者的血红蛋白从6.4g/dL增加到9.4g/dL在阿米奥达龙治疗四天内.
结论:
- 阿米奥达龙对包括红细胞在内的各种细胞类型的已知影响表明,改善SCD的潜在机制.
- 这一案例表明,阿米奥达龙可能对红细胞脂质组成产生积极影响,可能减少形和贫血.
- 需要进一步的临床研究来验证amiodarone作为治疗状细胞危机的治疗选择.
更多相关视频
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.7K
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.8K
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
29
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
29
01:28Acute Coronary Syndrome IV: Interprofessional Care
13
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
13
01:30Cardiomyopathy II: Dilated Cardiomyopathy
12
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12
01:25Dysrhythmias VI: Management of Dysrhythmias
19
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19
01:26Acute Coronary Syndrome V: Nursing Management
18
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
18
01:26Heart Failure Drugs: Inotropic Agents
641
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
641